These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28445592)

  • 1. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
    Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
    Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes.
    Foca A; Dhillon A; Lahlali T; Lucifora J; Salvetti A; Rivoire M; Lee A; Durantel D
    Antivir Ther; 2020; 25(3):151-162. PubMed ID: 32496211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication.
    Wang WH; Studach LL; Andrisani OM
    Hepatology; 2011 Apr; 53(4):1137-47. PubMed ID: 21480320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5A.
    Chen YC; Su WC; Huang JY; Chao TC; Jeng KS; Machida K; Lai MM
    J Virol; 2010 Aug; 84(16):7983-93. PubMed ID: 20534861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.
    Studach LL; Menne S; Cairo S; Buendia MA; Hullinger RL; Lefrançois L; Merle P; Andrisani OM
    Hepatology; 2012 Oct; 56(4):1240-51. PubMed ID: 22505317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
    Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
    Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
    Studach LL; Rakotomalala L; Wang WH; Hullinger RL; Cairo S; Buendia MA; Andrisani OM
    Hepatology; 2009 Aug; 50(2):414-23. PubMed ID: 19472310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production.
    Chabrolles H; Auclair H; Vegna S; Lahlali T; Pons C; Michelet M; Couté Y; Belmudes L; Chadeuf G; Kim Y; Di Bernardo A; Jalaguier P; Cosset FL; Fusil F; Rivoire M; Arnold LD; Lopatin U; Combet C; Zoulim F; Grierson D; Chabot B; Lucifora J; Durantel D; Salvetti A
    PLoS Pathog; 2020 Nov; 16(11):e1008593. PubMed ID: 33180834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100.
    Huang YH; Tseng YH; Lin WR; Hung G; Chen TC; Wang TH; Lee WC; Yeh CT
    Oncotarget; 2016 Feb; 7(8):9448-61. PubMed ID: 26824500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
    Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
    Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis.
    Li TN; Wu YJ; Tsai HW; Sun CP; Wu YH; Wu HL; Pei YN; Lu KY; Yen TT; Chang CW; Chan HL; Tao MH; Liou JY; Chang MD; Su IJ; Wang LH
    J Pathol; 2018 Aug; 245(4):502-513. PubMed ID: 29862509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
    Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
    Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
    J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
    Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
    Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
    Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
    Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.